- Review
Anxiety and depression are prevalent neuropsychiatric disorders, and Lamiaceae species have shown neuroprotective and psychotropic properties. However, no systematic review with quantitative synthesis has specifically assessed phytochemically characterized Lamiaceae extracts in preclinical models of these disorders. This study reviewed and meta-analyzed the available evidence following PRISMA 2020 guidelines. Searches of EMBASE, MEDLINE, ScienceDirect, Scopus, and Web of Science through May 2026 identified controlled studies evaluating phytochemically characterized whole-plant extracts. Risk of bias was assessed using SYRCLE, and random-effects meta-analyses with the Knapp–Hartung adjustment were performed. Nine studies met the inclusion criteria. A significant anxiolytic-like effect was observed in the Open Field Test (SMD = 2.81, 95% CI: 1.37–4.24; k = 3), whereas Elevated Plus Maze and Hole-Board Test results favored treatment but were not statistically significant. For depression-like behavior, immobility was reduced in the Tail Suspension Test (TST; SMD = −2.44, 95% CI: −3.09 to −1.79; k = 3). However, this result was sensitive to sex-based data selection: substituting male for female offspring data from one study rendered the effect non-significant and introduced substantial heterogeneity. The primary Forced Swimming Test (FST) analysis was also non-significant (SMD = −3.75, 95% CI: −8.01 to 0.52; k = 8), with a significant reduction in immobility observed only after excluding a highly influential study (SMD = −1.73, 95% CI: −2.49 to −0.97; k = 7). Reported biological effects included antioxidant, neuroprotective, and neuromodulatory actions involving GABAergic, serotonergic, cholinergic, and neurotrophic pathways. Given the small number of studies, imprecise estimates, and incomplete methodological reporting, these findings suggest rather than establish the therapeutic potential of phytochemically characterized Lamiaceae extracts. Further studies using standardized protocols are needed to strengthen the evidence and support translational research.
10 November 2026


